MD, Chief Physician. He has long been engaged in clinical practice and scientific research in medical oncology and received training at Memorial Sloan‑Kettering Cancer Center in the United States. He possesses extensive clinical experience in malignant melanoma. He has been dedicated to clinical diagnosis and treatment, scientific research and talent development focusing on systemic therapy and complication management of malignant melanoma and genitourinary tumors (e.g., urothelial carcinoma, renal cell carcinoma, prostate cancer, germ cell tumors). He pioneered multiple internationally cutting‑edge therapeutic techniques in China and actively participated in formulating and updating Chinese clinical practice guidelines for malignant melanoma, urothelial carcinoma, renal cell carcinoma and other malignancies. His research findings have been repeatedly published in authoritative oncology journals at home and abroad including JCO, CCR and EJC, which has greatly advanced the clinical management standards and international influence of melanoma and genitourinary tumors in China. He has taken part in numerous domestic and international clinical trials and served as a key investigator in the pre‑marketing clinical trial of toripalimab, China’s first anti‑PD‑1 monoclonal antibody. As a major contributor, he has been awarded the Third‑Class Prize of the Chinese Medical Science and Technology Award, the Second‑Class Prize of the Beijing Science and Technology Award, the Second‑Class Prize of the China Anti‑Cancer Association Science and Technology Award, and the Third‑Class Prize of the Huaxia Medical Science and Technology Award.